Komplikationen der Leberzirrhose

B Appenrodt; J Trebicka; T Sauerbruch

doi:10.1055/s-0031-1281563

DMW - Deutsche Medizinische Wochenschrift, Table of Contents

Dtsch Med Wochenschr 2011; 136(31/32): 1601-1604
DOI: 10.1055/s-0031-1281563

Verdauungs- und Stoffwechselkrankheiten | Commentary

Gastroenterologie, Hepatologie
© Georg Thieme Verlag KG Stuttgart · New York

Komplikationen der Leberzirrhose

Complications of liver cirrhosisB. Appenrodt¹ , J. Trebicka¹ , T. Sauerbruch¹

¹Medizinische Klinik und Poliklinik I, Universitätsklinik Bonn

Abstract

Schlüsselwörter

Leberzirrhose - Ösophagusvarizen - Aszites - hepatische Enzephalopathie

Keywords

liver cirrhosis - esophageal varices - ascites - hepatic encephalopathy

Full Text

References

Literatur

1 Appenrodt B, Grunhage F, Gentemann M G. et al . Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology. 2010; 51 1327-1333
2 Appenrodt B, Lehmann L E, Thyssen L. et al . Is detection of bacterial DNA in ascitic fluid of clinical relevance?. Eur J Gastroenterol Hepatol. 2010; 22 1487-1494
3 Arvaniti V, D’Amico G, Fede G. et al . Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology. 2010; 139 1246-1256, 1256.e1 – 5
4 Bajaj J S, Heuman D M, Wade J B. et al . Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology. 2010; 140 478-487 e471
5 Bajaj J S, Saeian K, Schubert C M. et al . Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology. 2009; 50 1175-1183
6 Bass N M, Mullen K D, Sanyal A. et al . Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010; 362 1071-1081
7 Bruno S, Crosignani A, Facciotto C. et al . Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology. 2010; 51 2069-2076
8 Bruns T, Sachse S, Straube E. et al . Identification of bacterial DNA in neutrocytic and non-neutrocytic cirrhotic ascites by means of a multiplex polymerase chain reaction. Liver Int. 2009; 29 1206-1214
9 Castellote J, Lopez C, Gornals J. et al . Rapid diagnosis of spontaneous bacterial peritonitis by use of reagent strips. Hepatology. 2003; 37 893-896
10 de Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2010; 53 762-768
11 de la Pena J, Brullet E, Sanchez-Hernandez E, Rivero M, Vergara M, Martin-Lorente J L, Garcia S uarez C. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial. Hepatology. 2005; 41 572-578
12 Garcia-Pagan J C, Caca K, Bureau C. et al . Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med. 2010; 362 2370-2379
13 Gerbes A L, Huber E, Gulberg V. Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i. v. bolus administration. Gastroenterology. 2009; 137 1179
14 Gines P, Wong F, Watson H. et al . Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology. 2008; 48 204-213
15 Gonzalez R, Zamora J, Gomez-Camarero J, Molinero L M, Banares R, Albillos A. Meta-analysis: Combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis. Ann Intern Med. 2008; 149 109-122
16 Martin-Llahi M, Pepin M N, Guevara M. et al . Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008; 134 1352-1359
17 Mishra S R, Sharma B C, Kumar A, Sarin S K. Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers: A randomized controlled trial. J Hepatol. 2010 Nov 5. [Epub ahead of print];
18 Monescillo A, Martínez-Lagares F, Ruiz-del-Arbol L. et al . Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology. 2004; 40 793-801
19 Nischalke H D, Berger C, Aldenhoff K. et al . Toll-like receptor (TLR) 2 promotor and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. J Hepatol. 2011; Feb 25. [Epub ahead of print];
20 Nousbaum J B, Cadranel J F, Nahon P. et al . Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis. Hepatology. 2007; 45 1275-1281
21 Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007; 56 1310-1318
22 Sanyal A J, Boyer T, Garcia-Tsao G. et al . A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008; 134 1360-1368
23 Sersté T, Bert F, Leflon-Guibout V. et al . Detection of bacterial DNA in serum and ascitic fluid of asymptomatic outpatients with cirrhosis and non-neutrocytic ascites. Liver Int. 2011; 31 494-498
24 Sharma B C, Sharma P, Agrawal A, Sarin S K. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology. 2009; 137 885-891
25 Sharma P, Sharma B C, Sarin S K. Predictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy. Eur J Gastroenterol Hepatol. 2010; 22 526-531
26 Tripathi D, Ferguson J W, Kochar N. et al . Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology. 2009; 50 825-833
27 Wong F, Gines P, Watson H. et al . Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol. 2010; 53 283-290
28 Zapater P, Francés R, González-Navajas J M. et al . Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis. Hepatology. 2008; 48 1924-1931

Dr. med. B. Appenrodt
Dr. med. J. Trebicka

Universitätsklinik Bonn
Medizinische Klinik und Poliklinik I

Sigmund-Freud-Str. 25

53105 Bonn

Phone: 0228/2871-5507

Fax: 0228/2871-5768

Email: beate.appenrodt@ukb.uni-bonn.de

Email: jonel.trebicka@ukb.uni-bonn.de